TP53 and breast neoplasm: In order to evaluate whether ARV-825 would also be effective against p53 mutant ER+ breast tumors treated with the Fulvestrant + Palbociclib combination, we assessed the temporal response by real time, live cell imaging using IncuCyte S3 in T-47D breast tumor cells.